| SEQ_NO | 3 | Date of announcement | 2024/06/12 | Time of announcement | 15:13:50 |
| Subject | Medeon approved to release newly elected Directors or representatives from Non-Competition Restrictions at the Annual Shareholders' Meeting | ||||
| Date of events | 2024/06/12 | To which item it meets | paragraph 21 | ||
| Statement | 1.Date of the shareholders’ meeting resolution:2024/06/12 2.Name and title of the managerial officer with permission to engage in competitive conduct: CENTER LABORATORIES INC. ; Director Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin; Director Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu; Director Legal Representative of Medeon, Inc., Yue Teh Jang; Director Chi Hang Yang; Independent Director Chia Ying Ma; Independent Director Jien Wei Yeh; Independent Director 3.Items of competitive conduct in which the officer is permitted to engage: Invest in or manage other companies with the same or similar scope of business as Medeon Biodesign, Inc. 4.Period of permission to engage in the competitive conduct: During the period of serving as director of Medeon Biodesign, Inc. 5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act): Shares represented at the time of voting: 52,090,101 rights Number of voting rights of shareholders present at the time of voting Votes in favor 51,633,784 votes?APercentage of the total represented share present 99.12% Votes against 166,110 votes?APercentage of the total represented share present 0.31% Votes invalid 0 votes?APercentage of the total represented share present 0.00% Votes abstained 290,207 votes?APercentage of the total represented share present 0.55% 6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter ‘N/A’ below): Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin; Director 7.Company name of the mainland China enterprise and the officer’s position in the enterprise: Director, Beijing Shundu Pharmaceutical Research Institute Co., Ltd. Director, Shanghai Bio Pharmaceuticals Co., Ltd. Director, Scindy Pharmaceutical (SuZhou), Ltd. 8.Address of the mainland China enterprise: Beijing Shundu Pharmaceutical Research Institute Co., Ltd.?GRoom 904, 9th Floor, No. 61, West Balizhuang Li, Chaoyang District, Beijing Shanghai Bao Pharmaceuticals Co., Ltd?GNo. 28 Luoxin Road, Baoshan District, Shanghai Scindy Pharmaceutical (Suzhou) Co., Ltd.?GAddress: 6 / F, Block B, Building 4, No. 108 Yuxin Road, Suzhou Industrial Park, Suzhou, Jiangsu, P.R.China 9.Operations of the mainland China enterprise: Beijing Shundu Pharmaceutical Research Institute Co., Ltd.?G Biotechnology Services Shanghai Bio Pharmaceuticals Co., Ltd.?G Development of Recombinant Protein Drugs and Antibody Drugs Scindy Pharmaceutical (SuZhou), Ltd.?G Medical Research and Trial Development 10.Impact on the company’s finance and business:N/A 11.If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio:N/A 12.Any other matters that need to be specified:None |
||||